12
ALL12
PhilogenYear
12
ALL3
20244
20233
20222
2020DEALS // DEV.
12
ALL3
Deals9
DevelopmentsCountry
12
ALL12
ITALY12
ALL7
Inapplicable1
Merck & Co3
Sun Pharmaceutical Industries Limited1
University Hospital ZürichTherapeutic Area
12
ALL12
OncologyStudy Phase
12
ALL8
Phase III1
Phase II2
Phase I/ Phase II1
UndisclosedDeal Type
12
ALL1
Collaboration9
Inapplicable2
Licensing AgreementProduct Type
12
ALL2
Other Large Molecule10
ProteinDosage Form
12
ALL1
Intralesional Injection6
Intratumoral Injection2
Intravenous Infusion1
Subcutaneous Injection2
UndisclosedLead Product
12
ALL8
Bifikafusp Alpha1
Doxorubicin2
Fibromun1
Onfekafusp AlphaTarget
12
ALL1
Angiogenesis6
IL-2 receptor1
PD-L14
UndisclosedPhilogen and Sun Pharma seek EMA approval for melanoma therapy
Details : Announced the filing of a marketing authorisation application with the European Medicines Agency for Nidlegy, an investigational neoadjuvant therapy, for locally advanced, fully resectable melanoma.
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : Onfekafusp Alpha,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Philogen Updates on Ph III Trial of Onfekafusp Alfa in Advanced Soft Tissue Sarcoma
Details : L19TNF (onfekafusp alfa), a homotrimer peptide fused to human TNF, is being evaluated with doxorubicin for first-line treatment of advanced or metastatic soft tissue sarcoma.
Product Name : Fibromun
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 20, 2024
Lead Product(s) : Onfekafusp Alpha,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sun Pharma, Philogen Ink Licensing Deal for Cancer Drug Firbomun
Details : The agreement aims for the commercialisation of Fibromun (onfekafusp alfa), being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma.
Product Name : Fibromun
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 10, 2024
Details : Nidlegy (bifikafusp alfa & onfekafusp alfa) is designed for the treatment of skin cancer. It consists of two active ingredients, L19IL2 and L19TNF which are manufactured independently, and which are mixed prior to intralesional administration.
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Inapplicable
October 16, 2023
Sun Pharma and Philogen Sign Licence Agreement for Anti-Cancer Therapy
Details : Under the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy (bifikafusp alfa), a new anti-cancer biopharmaceutical, being developed by Philogen for melanoma and non-melanoma skin cancers, in the territories of Europe, Australia an...
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Undisclosed
May 30, 2023
Lead Product(s) : Fibromun,Lomustine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : University Hospital Zürich
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : L19TNF is a fully-human immunomodulatory product consisting of the L19 antibody and TNF. The L19 antibody is specific to the EDB domain of fibronectin and mediates selective localization of TNF to the site of disease while sparing healthy organs.
Product Name : L19TNF
Product Type : Protein
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : Fibromun,Lomustine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : University Hospital Zürich
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bifikafusp Alpha,Onfekafusp Alpha
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Philogen Announces Clinical Trial Collaboration with MSD
Details : Under the supply agreement, MSD provides their anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), to be evaluated in combination with Philogen's immunocytokines L19IL2, L19TNF, and Nidlegy (bifikafusp alfa) in a randomized Phase II clinical trial in unresect...
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Undisclosed
January 06, 2023
Lead Product(s) : Bifikafusp Alpha,Onfekafusp Alpha
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Nidlegy (bifikafusp alfa) is combination of the immunocytokines L19IL2 and L19TNF, which is being developed as intralesional treatment for patients with advanced locoregional melanoma and non-melanoma skin cancers.
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Inapplicable
July 25, 2022
Details : Nidlegy™, the combination of the two active principles bifikafusp alfa (L19IL2) and onfekafusp alfa (L19TNF), has already shown promising results in the intralesional treatment of patients with advanced melanoma and in BCC and cSCC in an ongoing Phase ...
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Inapplicable
February 17, 2022
Details : Nidlegy, as a neoadjuvant was found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated in PIVOTAL phase III trial in melanoma patients with locally advanced, fully resectable metastatic cancer.
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Inapplicable
January 13, 2022